BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia
Shots:
- BioMarin has submitted an NDA to the US FDA for vosoritide to treat children with achondroplasia
- The company also reported that EMA has begun validation of MAA for the therapy on 13 Aug- 2020
- Vosoritide is an investigational- once-daily injection analog of C-type Natriuretic Peptide (CNP) and is potentially the first treatment for achondroplasia in the US
Ref: Biomarin | Image: Fierce Biotech
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
